NCT03325075

Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants

A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of VAL-181388 in Healthy Adults in a Non-endemic Chikungunya Region

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: ModernaTX, Inc. · Industry
• Sex: All
• Age: 18 Years – 49 Years
• Healthy volunteers: Accepted

Summary

This clinical study will assess the safety, tolerability, and immunogenicity of VAL-181388 in healthy participants.

Conditions

• Chikungunya Virus

Interventions

Type	Name	Description
BIOLOGICAL	VAL-181388	Escalating dose levels
OTHER	Placebo	Saline

Timeline

• Start date: 2017-07-19
• Primary completion: 2019-03-19
• Completion: 2019-03-19
• First posted: 2017-10-30
• Last updated: 2024-06-10
• Results posted: 2024-06-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study